Displaying drugs 2126 - 2150 of 3211 in total
AUM-601
AUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.
Investigational
EVT 201
EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
Investigational
Matched Iupac: … 1,2,4-oxadiazol-3-yl}-8-methyl-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,11,13-pentaen-9- …
DDP-200
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
AMG-208
AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.
Investigational
OCE-205
Investigational
EDI-200
EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Investigational
HMI-204
HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
Investigational
RGX-202
RGX-202 is a recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin).
Investigational
APD-209
Investigational
Cavrotolimod
Investigational
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
TAK-901
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Investigational
SR-9009
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
SR-9011
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
GS-9191
GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Investigational
Matched Iupac: … 2-methylpropyl (2S)-2-{[({2-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]ethoxy}methyl)({[(2S)-1-(2-methylpropoxy …
ILS-920
ILS-920 is under investigation in clinical trial NCT00827190 (Study Evaluating Single Ascending Doses Of ILS-920).
Investigational
REC-994
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Investigational
OBI-999
Investigational
Neovastat
Neovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer.
Investigational
WRR-99
Experimental
AGF-94
Investigational
Displaying drugs 2126 - 2150 of 3211 in total